EirGenix

Overview
News
Biosimilars?
Product stageSegments
Growth
?
Contract Development and Manufacturing Organizations
?

EirGenix is a biopharmaceutical company specializing in the development and manufacturing of biosimilar drugs, with a focus on treatments for HER2-positive breast cancer and metastatic gastric cancers. The company's primary product is EG12014, a trastuzumab biosimilar of Roche's Herceptin. In November 2023, EG12014 received marketing authorization from the European Commission for the treatment of HER2-positive breast cancer and metastatic gastric cancers. EirGenix is also developing EG1206A, a biosimilar of Roche's Perjeta (pertuzumab), which successfully completed its Phase 1 clinical trial in April 2023. The company's product pipeline includes five antibody products for HER2-positive breast cancer treatment.

EirGenix offers contract services for biologics, including process development, analytical services, and current Good Manufacturing Practice (cGMP) production in microbial and mammalian systems. The company has assisted clients with biological products from preclinical development to commercial manufacturing. EirGenix's facilities have been inspected and certified by Taiwan's FDA as Pharmaceutical Inspection Co-operation Scheme GMP-compliant. In 2020, EirGenix became the first biopharmaceutical facility in Taiwan to receive approval from Japan's Pharmaceutical and Medical Device Agency. The company's production capacity expanded with the completion of a second production line at its Zhubei Commercial Production Facility in Q3 2023, bringing its total production capacity to 25,500 liters.


Sources

Disclaimer: This company profile has been generated using data obtained through automated web searches and advanced generative AI technology. While we strive to ensure the accuracy and reliability of our sources, auto-generated information could be outdated or inaccurate and should be verified independently.
HQ location:
Taipei TWN
Founded year:
2012
Employees:
51-100
IPO status:
Private
Total funding:
-
Last Funding:
-
Last valuation:
-
Key competitors
Filter by the segments to which the disruptor belongs
All Segmentsexpand
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.